PDCD1LG2 and cancer: Currently, there are no established markers available for monitoring immune dysfunction in cancer patients.38 We propose that in contrast to PD‐L2, systemic PD‐L1 expression should be investigated as potential parameter for monitoring systemic immune dysfunction in cancer.